Windward Bio secured $165 million to support clinical trials in asthma, COPD, and additional respiratory and dermatological indications. The company said the funding backs a lead long-acting antibody program and a second antibody platform positioned for dosing advantages versus existing biologics. The round emphasizes investors’ continued willingness to fund late preclinical and early clinical assets in respiratory immunology where durability and convenience are key competitive differentiators. For the biotech sector, a large multi-program financing can reduce runway pressure while the company completes dose-ranging, expansion cohorts, and proof-of-concept endpoints. Although specific trial designs and timelines were not included in the excerpt, the financing magnitude suggests Windward intends to run development with sufficient scale to generate decision-grade efficacy and safety data.